Who are amoxicillin or moxifloxacin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEPHALEXIN, Ceftolozane-tazobactam + Meropenem, Cefadroxil discontinued early, Cefadroxil until drain removal, Ceftazidime-avibactam + Aztreonam, CREXONT ER.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amoxicillin-or-moxifloxacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

amoxicillin or moxifloxacin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

amoxicillin or moxifloxacin (amoxicillin or moxifloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Penicillin antibiotic. Area: Infectious diseases.

phase 3 Penicillin antibiotic Penicillin-binding proteins Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

amoxicillin or moxifloxacin (amoxicillin or moxifloxacin) — Centre Hospitalier Universitaire de Nice. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amoxicillin or moxifloxacin TARGET	amoxicillin or moxifloxacin	Centre Hospitalier Universitaire de Nice	phase 3	Penicillin antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Ceftolozane-tazobactam + Meropenem	Ceftolozane-tazobactam + Meropenem	National University of Singapore	marketed	Beta-lactam antibiotic combination	Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition
Cefadroxil discontinued early	Cefadroxil discontinued early	Stony Brook University	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefadroxil until drain removal	Cefadroxil until drain removal	Stony Brook University	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
Ceftazidime-avibactam + Aztreonam	Ceftazidime-avibactam + Aztreonam	National University of Singapore	marketed	β-lactam antibiotic combination with β-lactamase inhibitor	Bacterial penicillin-binding proteins; β-lactamases
CREXONT ER	CREXONT ER	Impax Laboratories, LLC	marketed	First-generation cephalosporin antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Penicillin antibiotic class)

Belén Retamal-Valdes · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amoxicillin or moxifloxacin — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-or-moxifloxacin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab